7 Matching Annotations
  1. Last 7 days
  2. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov
    Pathogenesis of Noonan Syndrome is Modulated by NOC2L, a Novel Interactor of LZTR1 Leading to Impaired P53 Signalling
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    pmc.ncbi.nlm.nih.gov/articles/PMC13099202/
  3. Jun 2025
  4. pubs.acs.org pubs.acs.org
    Expression of a RAS Degrader via Synthetic Nanocarrier-Mediated mRNA Delivery Reduces Pancreatic Tumors
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    pubs.acs.org/doi/full/10.1021/acsabm.5c00179
  5. Jul 2024
  6. www.ncbi.nlm.nih.gov www.ncbi.nlm.nih.gov
    Therapeutic expression of RAS Degrader RRSP in Pancreatic Cancer via Nanocarrier-mediated mRNA delivery
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    ncbi.nlm.nih.gov/pmc/articles/PMC11212117/
  7. Aug 2022
  8. www.sciencedirect.com www.sciencedirect.com
    Non-degradable autophagic vacuoles are indispensable for cell competition
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    sciencedirect.com/science/article/pii/S2211124722011123
  9. May 2022
  10. www.sciencedirect.com www.sciencedirect.com
    ARAF protein kinase activates RAS by antagonizing its binding to RASGAP NF1
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    sciencedirect.com/science/article/pii/S1097276522004348
  11. aacrjournals.org aacrjournals.org
    Proteolytic pan-RAS cleavage leads to tumor regression in patient-derived pancreatic cancer xenografts
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    aacrjournals.org/mct/article/21/5/810/694769/Proteolytic-pan-RAS-Cleavage-Leads-to-Tumor
  12. Jul 2021
  13. academic.oup.com academic.oup.com
    An immune-competent, replication-permissive Syrian Hamster glioma model for evaluating Delta-24-RGD oncolytic adenovirus
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    academic.oup.com/neuro-oncology/advance-article-abstract/doi/10.1093/neuonc/noab128/6290257